Evidence map›Paper›PMID 30915108›Full record

ArticleFrontiers in genetics2019

Utility of cfDNA Fragmentation Patterns in Designing the Liquid Biopsy Profiling Panels to Improve Their Sensitivity.

Maxim Ivanov, Polina Chernenko, Valery Breder, Konstantin Laktionov, Ekaterina Rozhavskaya, Sergey Musienko, Ancha Baranova, Vladislav Mileyko

Abstract read
In one paragraph

Article in Frontiers in genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Circulating cell-free DNA for cancer early detection.Innovation (Cambridge (Mass.)) · 2022
    Review
  6. The utility of cfDNA in TGCT patient management: a systematic review.Therapeutic advances in medical oncology · 2022
    Review
  7. Properties and Application of Cell-Free DNA as a Clinical Biomarker.International journal of molecular sciences · 2021
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maxim IvanovDepartment of Biological and Medical Physics, Moscow Institute of Physics and Technology, Dolgoprudny, Russia.
Polina ChernenkoN.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
Valery BrederN.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
Konstantin LaktionovN.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
Ekaterina RozhavskayaAtlas Oncology Diagnostics, Ltd., Moscow, Russia.
Sergey MusienkoAtlas Oncology Diagnostics, Ltd., Moscow, Russia.
Ancha BaranovaDepartment of Biological and Medical Physics, Moscow Institute of Physics and Technology, Dolgoprudny, Russia.
Vladislav MileykoAtlas Oncology Diagnostics, Ltd., Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genotyping of cell-free DNA (cfDNA) in plasma samples has the potential to allow for a noninvasive assessment of tumor biology, avoiding the inherent shortcomings of tissue biopsy. Next generation sequencing (NGS), a leading technology for liquid biopsy analysis, continues to be hurdled with several major issues with cfDNA samples, including low cfDNA concentration and high fragmentation. In this study, by employing Ion Torrent PGM semiconductor technology, we performed a comparison between two multi-biomarker amplicon-based NGS panels characterized by a substantial difference in average amplicon length. In course of the analysis of the peripheral blood from 13 diagnostic non-small cell lung cancer patients, equivalence of two panels, in terms of overall diagnostic sensitivity and specificity was shown. A pairwise comparison of the allele frequencies for the same somatic variants obtained from the pairs of panel-specific amplicons, demonstrated an identical analytical sensitivity in range of 140 to 170 bp amplicons in size. Further regression analysis between amplicon length and its coverage, illustrated that NGS sequencing of plasma cfDNA equally tolerates amplicons with lengths in the range of 120 to 170 bp. To increase the sensitivity of mutation detection in cfDNA, we performed a computational analysis of the features associated with genome-wide nucleosome maps, evident from the data on the prevalence of cfDNA fragments of certain sizes and their fragmentation patterns. By leveraging the support vector machine-based machine learning approach, we showed that a combination of nucleosome map associated features with GC content, results in the increased accuracy of prediction of high inter-sample sequencing coverage variation (areas under the receiver operating curve: 0.75, 95% CI: 0.750-0.752 vs. 0.65, 95% CI: 0.63-0.67). Thus, nucleosome-guided fragmentation should be utilized as a guide to design amplicon-based NGS panels for the genotyping of cfDNA samples.

Indexed as

ampliconcancercfDNADNA fragmentationliquid biopsyNGSnucleosomeprimer design

Identifiers

PMID30915108
PMCPMC6422983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.